膀胱癌分子靶向药物不良反应的研究进展

Research Progress in Adverse Effects of Molecular Targeted Drugs for Bladder Cancer

膀胱癌是泌尿系统最常见的恶性肿瘤之一,尽管大多数膀胱癌为非肌层浸润,经尿道膀胱肿瘤电切可使大部分患者获益,但复发率高,易发生远处转移,晚期或转移性膀胱癌的疗效欠佳,预后差。随着人们对肿瘤细胞信号通路研究的不断深入,针对特定通路的靶向治疗越来越多地应用于临床,由于分子靶向药物作用的精确性,其被用于多种肿瘤(如晚期或转移性膀胱癌)的治疗,且取得了一定疗效,但其治疗相关不良反应逐渐引起人们的重视。

Bladder cancer is one of the most common malignant tumors in urinary system.Although most bladder cancers are non-muscle invasive,and transurethral resection of bladder tumor can benefit most patients,it has a high recurrence rate and is prone to distant metastasis.The patients with advanced or metastatic bladder cancer often have unsatisfactory therapeutic effect and poor prognosis.With the deepening of research on tumor cell signaling pathways,targeted therapy for specific pathways has been increasingly applied in clinic.Due to the accuracy of molecular targeted drugs,they have been used in the treatment of various tumors,such as advanced or metastatic bladder cancer,and have achieved certain results.However,the related adverse effects have gradually occurred attracting the attention of people.